Genome‐wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common pathological subtype of kidney cancer. Here, we integrated an unbiased genome‐wide RNA interference screen for ccRCC survival regulators with an analysis of recurrently overexpressed genes in ccRCC to identify new therapeutic targets in this disease. One of the most potent survival regulators, the monocarboxylate transporter MCT4 (SLC16A3), impaired ccRCC viability in all eight ccRCC lines tested and was the seventh most overexpressed gene in a meta‐analysis of five ccRCC expression datasets. MCT4 silencing impaired secretion of lactate generated through glycolysis and induced cell cycle arrest and apoptosis. Silencing MCT4 resulted in intracellular acidosis, and reduction in intracellular ATP production together with partial reversion of the Warburg effect in ccRCC cell lines. Intra‐tumoural heterogeneity in the intensity of MCT4 protein expression was observed in primary ccRCCs. MCT4 protein expression analysis based on the highest intensity of expression in primary ccRCCs was associated with poorer relapse‐free survival, whereas modal intensity correlated with Fuhrman nuclear grade. Consistent with the potential selection of subclones enriched for MCT4 expression during disease progression, MCT4 expression was greater at sites of metastatic disease. These data suggest that MCT4 may serve as a novel metabolic target to reverse the Warburg effect and limit disease progression in ccRCC. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
limma: Linear Models for Microarray Data
Smyth, G. K. (2005) · Statistics for Biology and Health · doi:10.1007/0-387-29362-0_23 · Cited by 5,796
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 2×
“Aerobic glycolysis can also be induced by oncogene activation, such as MYC amplification, or loss of certain tumour suppressors such as PTEN [28], both of which are Copyright 2012 Pathological Society of Great Britain and Ireland.”
BackgroundMotzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Cancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452 · cited 2×
“High rates of glucose uptake and lactate secretion are features of the WE that contribute to support ATP production and provide intermediates for biosynthesis in many tumours [12,13,26].”
BackgroundMetabolic flux and the regulation of mammalian cell growth
Locasale, J. W., & Cantley, L. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.07.014 · Cited by 449 · cited 1×
“Accumulation of intracellular lactate may also inhibit its conversion from pyruvate by lactate dehydrogenase [32], the main reaction regenerating NAD+ in highly glycolytic cells [33].”
BackgroundShlomi, T., Benyamini, T., Gottlieb, E., Sharan, R., & Ruppin, E. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002018 · Cited by 244
Almeida, A., Bolaños, J. P., & Moncada, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913668107 · Cited by 166 · cited 1×
“Silencing of MCT4 also led to a G2/M cell cycle arrest, indicating that there may be additional links between metabolism and cell cycle progression apart from those described recently [34].”
Result
Cited by
Targeting lactate metabolism for cancer therapeutics
Doherty, J. R., & Cleveland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69741 · Cited by 1,166
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940
“Interestingly, disruption of MCT1 or MCT4 in renal cell carcinoma, pancreatic cancer, breast cancer and prostate cancer has been shown to exert significant antitumor effects both in vivo and in vitro with increased accumulation of intracellular lactate (98, 99).”
BackgroundHow cancer metabolism is tuned for proliferation and vulnerable to disruption
Schulze, A., & Harris, A. L. (2012) · Nature · doi:10.1038/nature11706 · Cited by 929
Comprehensive review on lactate metabolism in human health
Adeva-Andany, M., López-Ojén, M., Funcasta-Calderón, R., Ameneiros-Rodríguez, E., Donapetry-García, C., Vila-Altesor, M., & Rodríguez-Seijas, J. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.05.007 · Cited by 615
Miess, H., Dankworth, B., Gouw, A. M., Rosenfeldt, M., Schmitz, W., Jiang, M., Saunders, B., Howell, M., Downward, J., Felsher, D. W., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0315-z · Cited by 361
“Among the VHL-mutant specific targets was SLC16A3, the gene coding for the lactate transporter MCT4, which has been shown previously to be essential for ccRCC cell survival [26].”
Self-citation
Metadata
- Authors
- Gerlinger, M., Santos, C. R., Spencer‐Dene, B., Martinez, P., Endesfelder, D., Burrell, R. A., Vetter, M., Jiang, M., Saunders, R. E., Kelly, G., Dykema, K., Rioux‐Leclercq, N., Stamp, G., Patard, J. J., Larkin, J., Howell, M., & Swanton, C.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2012-04-18
- Volume
- 227
- Issue
- 2
- Pages
- 146-156
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2062863565
- Cited by
- 106
- References
- 7
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.